Supernus Pharmaceuticals, Inc. (SUPN)

In the past six months, Supernus Pharmaceuticals reported strong Q3 2025 earnings and revenue, driven by demand for ONAPGO, Qelbree, and ZURZUVAE. ONAPGO faced supply constraints due to high demand. The company completed the acquisition of Sage Therapeutics, Inc., contributing to collaboration revenues from ZURZUVAE. Supernus increased its full-year 2025 revenue guidance. Q2 2025 results topped revenue expectations, although sales saw a slight year-on-year decline. The stock reached new 52-week highs. Analysts maintained "Buy" ratings and raised price targets. There was insider selling activity. The stock has seen a significant increase, being up 31% in the past year as of December 2025 and 52.38% in the past six months as of January 2026.

Information regarding demand seasonality for Supernus Pharmaceuticals' products is limited. Qelbree's net pricing was affected by seasonality in Q1 2025, suggesting some seasonal fluctuations in demand. Other products addressing chronic neurological conditions may have relatively stable demand, but specific seasonal patterns were not explicitly detailed.

Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for central nervous system diseases, including neurological and psychiatric disorders. The company's portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson's Disease, cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. Key products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, GOCOVRI, ONAPGO, and MYOBLOC. The company also has collaboration revenues from ZURZUVAE. Supernus is actively developing new CNS product candidates for various disorders.

Supernus Pharmaceuticals is headquartered in Rockville, Maryland, and primarily markets its products in the United States. The company also collaborates with channel partners to license its products outside the U.S.

Supernus Pharmaceuticals has generally maintained a positive brand reputation due to strong product performance and strategic management. The successful launch and demand for new products like ONAPGO and ZURZUVAE, along with sales growth for Qelbree and GOCOVRI, have contributed positively. Increased revenue guidance and positive analyst ratings reflect confidence. Supply constraints for ONAPGO are an operational challenge rather than a negative impact on brand reputation.

Supernus Pharmaceuticals is a publicly held company. Institutional investors hold a significant portion of the company's shares, ranging from approximately 24.11% to 95.9%. Major institutional owners include BlackRock, Inc., The Vanguard Group, Inc., Dimensional Fund Advisors L.P., Armistice Capital LLC, Point72 Asset Management, L.P., and State Street Corp. Individual insiders, including CEO Jack A. Khattar, hold approximately 4.04% to 4.29% of the company's stock.